Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 13	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 14	DEC 18	CA/CAplus patent kind codes updated
NEWS 15	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 17	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 19	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 22	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 23	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 24	JAN 29	PHAR reloaded with new search and display fields
NEWS 25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 26	FEB 13	CASREACT coverage to be extended
NEWS 27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:11:53 ON 23 FEB 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:12:08 ON 23 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 FEB 2007 HIGHEST RN 922800-14-4
DICTIONARY FILE UPDATES: 22 FEB 2007 HIGHEST RN 922800-14-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10823842c.str



chain nodes :
7 10 12 13 14
ring nodes :
1 2 3 4 5 6 11 15 16 17 18 19 20 21 22 23 24 25
chain bonds :
1-7 4-15 7-10 10-11 10-12 12-13 12-14

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-21 11-25 15-16 15-20 16-17 17-18 18-19
19-20 21-22 22-23 23-24 24-25
exact/norm bonds :
1-7 7-10
exact bonds :
4-15 10-11 10-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-21 11-25 12-13 12-14 15-16 15-20 16-17
17-18 18-19 19-20 21-22 22-23 23-24 24-25
isolated ring systems :
containing 1 : 15 :

G1:C,O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:12:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5 TO 234

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 16:12:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 195 TO ITERATE

100.0% PROCESSED 195 ITERATIONS 44 ANSWERS
SEARCH TIME: 00.00.01

L3 44 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 16:13:00 ON 23 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Feb 2007 VOL 146 ISS 10
FILE LAST UPDATED: 22 Feb 2007 (20070222/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 17 L3

=> s l4 and py<2003
22869415 PY<2003
L5 8 L4 AND PY<2003

=> d ibib abs hitstr tot

L5 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:671733 CAPLUS
DOCUMENT NUMBER: 137:201154
TITLE: Preparation of phenyl derivatives as inhibitors of factor Xa and factor VIIa
INVENTOR(S): Cezanne, Bertram; Juraszyk, Horst; Dorsch, Dieter; Tsaklakidis, Chistos; Gleitz, Johannes; Barnes, Christopher
PATENT ASSIGNEE(S): Merck Patent GmbH, Germany
SOURCE: Ger. Offen., 20 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10110325	A1	20020905	DE 2001-10110325	20010303 <--
CA 2439644	A1	20020912	CA 2002-2439644	20020204 <--
WO 2002070471	A1	20020912	WO 2002-EP1114	20020204 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1370522	A1	20031217	EP 2002-719754	20020204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200303437	A2	20040128	HU 2003-3437	20020204
JP 2004525119	T	20040819	JP 2002-569792	20020204
CN 1524072	A	20040825	CN 2002-805731	20020204
US 2004092517	A1	20040513	US 2003-469687	20030903
ZA 2003007715	A	20050103	ZA 2003-7715	20031002
PRIORITY APPLN. INFO.:			DE 2001-10110325	A 20010303
			WO 2002-EP1114	W 20020204

OTHER SOURCE(S): MARPAT 137:201154

GI



I

AB Title compds. [I; R1 = cyano, COR3, CO2R3, OR3, (amino protecting group-substituted) C(:NH)NH2, CON(R3)2, etc.; R2 = H, halo, A, OR3, N(R3)2, NO2, cyano, CO2R3, CON(R3)2, etc.; R3 = H, A, etc.; A = (branched) (O-, S-interrupted) (fluorinated) alkyl, alkenyl; W = NR3CO, NR3COC(R4)2, NR3C(R4)2, C(R4)2NR3C(R4)2; R4 = H, A; X = C(R3)2, [C(R3)2]2, C(R3)2O, C(R3)2NR3; Y = alkylene, cycloalkylene, (substituted) heterocycldiyl, etc; Z = OR3, N(R3)2, N(R3)2CON(R3)2, etc.], were prepared Thus, a mixture of (rac)-2-(2'-methanesulfonylbiphenyl-4-oxy)-2-phenylacetic acid (preparation given), 3-(methyl-1,2,4-oxadiazol-3-yl)aniline, and TBTU in DMF was stirred with 4-methylmorpholine for 20 h at room temperature to give (rac)-N-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-(2'-methanesulfonylbiphenyl-4-oxy)-2-phenylacetamide which was hydrogenated in the presence of Raney Ni for 18 h at room temperature to give (rac)-N-(3-amidinophenyl)-2-(2'-methanesulfonylbiphenyl-4-oxy)-2-phenylacetamide. The latter inhibited factor Xa with IC50 = 1.1·10-7 M and factor VIIa with IC50 = 4.6·10-8 M.

IT 452314-28-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amidinophenyls as inhibitors of factor Xa and factor VIIa)

RN 452314-28-2 CAPLUS

CN Benzeneacetic acid, α-[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:324943 CAPLUS
DOCUMENT NUMBER: 137:319942
TITLE: 3D-QSAR CoMFA and CoMSIA on protein tyrosine phosphatase 1B inhibitors
AUTHOR(S): Murthy, V. Sreenivasa; Kulkarni, Vithal M.
CORPORATE SOURCE: Pharmaceutical Technology and Pharmacy Division, Institute of Chemical Technology, University of Mumbai, Matunga, Mumbai, 400 019, India
SOURCE: Bioorganic & Medicinal Chemistry (2002), 10(7), 2267-2282
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 3D-QSAR and mol. modeling was performed on a series of benzofuran/benzothiophene biphenyls as protein tyrosine phosphatase 1B (PTP 1B) inhibitors with anti-hyperglycemic activity. Evaluation of 92 compds. served to establish the model, which was validated by evaluation of an external set of 26 compds. The lowest energy conformer of most active compound obtained from simulated annealing was used as a template structure for the alignment. The best predictions were obtained with the CoMFA model from RMS fit and A log P as addnl. descriptor (r2cv=0.615, r2=0.842), and with the CoMSIA combined steric, electrostatic, and lipophilic fields (r2cv=0.597, r2=0.910). The 3D-QSAR model was then superimposed to the PTP 1B active site, giving direct contour maps of the different fields. Further comparison of the contour maps from the 3D-QSAR showed high level of compatibility with the active site of PTP 1B enzyme.

IT 263759-84-8
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(3D-QSAR CoMFA and CoMSIA on protein tyrosine phosphatase 1B inhibitors)

RN 263759-84-8 CAPLUS
CN Benzeneacetic acid, α-[[4'-(2-butylbenzo[b]thien-3-yl)[1,1'-biphenyl]-4-yl]oxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:355085 CAPLUS
DOCUMENT NUMBER: 134:353250
TITLE: Preparation of α-(biphenylyloxo)alkanoic acids for treatment of insulin resistance and hyperglycemia
INVENTOR(S): Malamas, Michael S.; Mcdevitt, Robert E.; Adebayo, Folake O.
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: U.S., 30 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6232322	B1	20010515	US 1999-307972	19990510 <--
US 2001041715	A1	20011115	US 2001-798109	20010302 <--
US 6391897	B2	20020521		
US 2001053785	A1	20011220	US 2001-798088	20010302 <--
US 6369072	B2	20020409		

PRIORITY APPLN. INFO.: US 1998-113654P P 19980512
US 1998-76205 A 19980512
US 1999-307972 A3 19990510
OTHER SOURCE(S): MARPAT 134:353250
GI



I



II



III

AB The title compds. [I; A = II (wherein B = C; D = O, S, N; E = C; Y = a bond, CH2; CO, CHOH; R1 = alkyl, aryl, arylakyl, etc.; R2 = H, alkyl, alkoxy, etc.); R3, R4 = H, halo, alkyl, etc.; R5 = H, alkyl, etc.] were prepared as protein-tyrosine phosphatase inhibitors. Thus, 4-BrC6H4COCH2Br was etherified by PhOH and the cyclized product condensed with 4-(MeO)C6H4B(OH)2 to give, after O-demethylation, 3-(4'-hydroxybiphenylyl)benzofuran which was acylated by BzNMeOMe and the reduced product etherified by (R)-PhCH2CH(OH)CO2Me to give, after saponification, title compd (S)-III. Data for biol. activity of I were given.

IT 250341-86-7P 250341-99-2P 250342-02-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of α-(biphenylyloxo)alkanoic acids for treatment of insulin resistance and hyperglycemia)

RN 250341-86-7 CAPLUS
CN Benzeneacetic acid, α-[[4'-(3-benzofuranyl)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 250341-99-2 CAPLUS
CN Benzeneacetic acid, α-[[4'-[2-(phenylmethyl)-3-benzofuranyl][1,1'-biphenyl]-4-yl]oxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250342-02-0 CAPLUS
CN Benzeneacetic acid, α-[[4'-(2-butyl-3-benzofuranyl)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 98 THERE ARE 98 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:128048 CAPLUS
DOCUMENT NUMBER: 132:273845
TITLE: Novel Benzofuran and Benzothiophene Biphenyls as Inhibitors of Protein Tyrosine Phosphatase 1B with Antihyperglycemic Properties
AUTHOR(S): Malamas, Michael S.; Sredy, Janet; Moxham, Christopher; Katz, Alan; Xu, Weixin; McDevitt, Robert; Adebayo, Folake O.; Sawicki, Diane R.; Seestaller, Laura; Sullivan, Donald; Taylor, Joseph R.
CORPORATE SOURCE: Wyeth-Ayerst Research Inc., Princeton, NJ, 08543-8000, USA
SOURCE: Journal of Medicinal Chemistry (2000),

43(7), 1293-1310
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Insulin resistance in the liver and peripheral tissues, together with a pancreatic cell defect, are the common causes of Type 2 diabetes. It is now appreciated that insulin resistance can result from a defect in the insulin receptor signaling system, at a site post binding of insulin to its receptor. Protein tyrosine phosphatases (PTPases) have been shown to be neg. regulators of the insulin receptor. Inhibition of PTPases may be an effective method in the treatment of Type 2 diabetes. We have identified two novel series of benzofuran/benzothiophene biphenyl oxo-acetic acids and sulfonyl-salicylic acids as potent inhibitors of PTP1B with good oral antihyperglycemic activity. To assist in the design of these inhibitors, crystallog. studies have attempted to identify enzyme inhibitor interactions. Resolution of crystal complexes has suggested that the inhibitors bind to the enzyme active site and are held in place through hydrogen bonding and van der Waals interactions formed within two hydrophobic pockets. In the oxo-acetic acid series, hydrophobic substituents at position-2 of the benzofuran/benzothiophene biphenyl framework interacted with Phe182 of the catalytic site and were very critical to the intrinsic activity of the mol. The hydrophobic region of the catalytic-site pocket was exploited and taken advantage by hydrophobic substituents at either the α-carbon or the ortho aromatic positions of the oxo-acetic acid moiety. Similar ortho aromatic substitutions on the salicylic acid-type inhibitors had no effect, primarily due to the different orientation of these inhibitors in the catalytic site. The most active inhibitors of both series inhibited recombinant human PTP1B with phosphotyrosyl dodecapeptide TRDI(P)YETD(P)Y(P)YRK as the source of the substrate with IC50 values in the range of 20-50 nM. Compound I was one of the most active compds. in vivo, normalizing plasma glucose levels at the 25 mg/kg dose (po) and the 1 mg/kg dose (i.p.). Compound I was also selective against several other PTPases.

IT 250341-99-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties)

RN 250341-99-2 CAPLUS

CN Benzeneacetic acid, α-[[4'-[2-(phenylmethyl)-3-benzofuranyl][1,1'-biphenyl]-4-yl]oxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 263759-84-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties)
RN 263759-84-8 CAPLUS
CN Benzeneacetic acid, α-[[4'-(2-butylbenzo[b]thien-3-yl)[1,1'-biphenyl]-4-yl]oxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:736685 CAPLUS
DOCUMENT NUMBER: 131:351222
TITLE: Preparation of α-(biphenylyloxo)alkanoic acids for treatment of insulin resistance and hyperglycemia
INVENTOR(S): Malamas, Michael Sotirios; McDevitt, Robert Emmett; Adebayo, Folake Oluwemimo
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958518	A2	19991118	WO 1999-US10201	19990510 <--
WO 9958518	A3	20000120		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,

RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2330557	A1	19991118	CA 1999-2330557		19990510 <--
AU 9941836	A	19991129	AU 1999-41836		19990510 <--
EP 1077967	A2	20010228	EP 1999-925583		19990510 <--
EP 1077967	B1	20021204			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO					
JP 2002514635	T	20020521	JP 2000-548322		19990510 <--
AT 229015	T	20021215	AT 1999-925583		19990510 <--
PRIORITY APPLN. INFO.:			US 1998-76205	A	19980512
			WO 1999-US10201	W	19990510

OTHER SOURCE(S): MARPAT 131:351222
GI



I



II

AB Title compds. [I; R = 4-(R1Z1Z2)C6H4; R1 = (ar)alkyl, alkoxy, (hetero)aryl, etc.; Z1 = bond, CH2, CO, CH(OH); Z2 = (benz)imidazolylene, (benzo)furylene, thienylene, etc.; R3,R4 = H, halo, alkyl, alkoxy, etc.; R5 = H, alkyl, CH2CO2H, CHR8CH2CO2H, etc.; R8 = H, (ar)alkyl, aryl, etc.] were prepared as protein-tyrosine phosphatase inhibitors. Thus, 4-BrC6H4COCH2Br was etherified by PhOH and the cyclized product condensed with 4-(MeO)C6H4B(OH)2 to give, after O-demethylation, 3-(4'-hydroxybiphenylyl)benzofuran which was acylated by BzNMeOMe and the reduced product etherified by (R)-PhCH2CH(OH)CO2Me to give, after saponification, title compd (S)-II. Data for biol. activity of I were given.

IT 250341-86-7P 250341-99-2P 250342-02-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of α-(biphenylyloxo)alkanoic acids for treatment of insulin resistance and hyperglycemia)

RN 250341-86-7 CAPLUS
CN Benzeneacetic acid, α-[[4'-(3-benzofuranyl)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 250341-99-2 CAPLUS
CN Benzeneacetic acid, α-[[4'-[2-(phenylmethyl)-3-benzofuranyl][1,1'-biphenyl]-4-yl]oxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250342-02-0 CAPLUS
CN Benzeneacetic acid, α-[[4'-(2-butyl-3-benzofuranyl)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1975:496755 CAPLUS
DOCUMENT NUMBER: 83:96755
TITLE: Hydratropic acid derivatives
INVENTOR(S): Schacht, Erich; Mehrhof, Werner; Simane, Zdenek; Nowak, Herbert; Kayser, Detlev
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 29 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2358789	A1	19750605	DE 1973-2358789	19731126 <--
ZA 7405890	A	19750924	ZA 1974-5890	19740917 <--
CA 1059516	A1	19790731	CA 1974-213692	19741114 <--
AU 7475405	A	19760520	AU 1974-75405	19741115 <--
CS 176295	B2	19770630	CS 1974-8625	19741120 <--
BE 822496	A1	19750522	BE 1974-150763	19741122 <--
SE 7414704	A	19750527	SE 1974-14704	19741122 <--
FR 2252093	A1	19750620	FR 1974-38453	19741122 <--
FR 2252093	B1	19780908		
JP 50083345	A	19750705	JP 1974-136099	19741125 <--
DK 7406131	A	19750728	DK 1974-6131	19741125 <--
GB 1435050	A	19760512	GB 1974-50946	19741125 <--
US 4072754	A	19780207	US 1974-527089	19741125 <--
CH 605589	A5	19780929	CH 1974-15633	19741125 <--
CH 605590	A5	19780929	CH 1977-14185	19741125 <--

AT 351538	B	19790725	AT 1974-9432		19741125 <--
AT 7409432	A	19790115			
NL 7415414	A	19750528	NL 1974-15414		19741126 <--
HU 168666	B	19760628	HU 1974-ME1801		19741126 <--
DD 114399	A5	19750812	DD 1975-182563		19751125 <--
CS 176290	B2	19770630	CS 1976-7936		19761120 <--
CS 176294	B2	19770630	CS 1976-8624		19761120 <--
AT 7705438	A	19790615	AT 1977-5438		19770726 <--
AT 354449	B	19790110			
AT 7705439	A	19790615	AT 1977-5439		19770726 <--
AT 354450	B	19790110			
CH 617172	A5	19800514	CH 1977-14186		19771121 <--
PRIORITY APPLN. INFO.:			DE 1973-2358789	A	19731126
			AT 1974-9432	A	19741125
			CH 1974-15633		19741125

OTHER SOURCE(S): MARPAT 83:96755

AB 4-RC6H4OCMePhCO2H (I; R = e.g., H, Cl, Ph, 4-ClC6H4O, 1-pyrrolyl, 1,2,3,4-tetrahydro-4-quinolyl) were prepared by the reaction of 4-RC6H4OH with PhCMeBrCO2Et and Na in MeOH, followed by saponification Salts and esters of I were also prepared I were useful as cholesterol- and triglyceride-lowering agents; ED data were given.

IT 56855-38-0P 56855-39-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 56855-38-0 CAPLUS

CN Benzeneacetic acid, α-([1,1'-biphenyl]-4-yloxy)-α-methyl- (9CI) (CA INDEX NAME)



RN 56855-39-1 CAPLUS

CN Benzeneacetic acid, α-(4'-chloro[1,1'-biphenyl]-4-yloxy)-α-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	1973:536854 CAPLUS
DOCUMENT NUMBER:	79:136854
TITLE:	Amides and esters of phenoxyphenylacetic acids
INVENTOR(S):	Bolhofer, William A.
PATENT ASSIGNEE(S):	Merck and Co., Inc.
SOURCE:	Ger. Offen., 33 pp. CODEN: GWXXBX
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2307038	A1	19730906	DE 1973-2307038	19730213 <--
NL 7301246	A	19730816	NL 1973-1246	19730129 <--
CH 587794	A5	19770513	CH 1973-1901	19730209 <--
JP 48086842	A	19731115	JP 1973-16667	19730212 <--
GB 1388776	A	19750326	GB 1973-6789	19730212 <--
FR 2181725	A1	19731207	FR 1973-4988	19730213 <--

PRIORITY APPLN. INFO.: US 1972-226293 A 19720214

AB Seven RC6H4OCH(COR1)C6H4R2-4 [I; R = 3-allyl, 3-CF3, 4-PrCO, 4-PhNH, 4-ClC6H4, 4-(1,2,3,4-tetrahydro-1-naphthyl); R1 = OCH2CH2NHAc, OCH2CH2NHBr, NHCH2CO2H, NHCH2CH2Cl, OCH2Ph; R2 = Cl, OMe] and salts with cyclohexylamine or citric acid, useful as anticholesteremics, blood fat lowering drugs, and in the treatment of atherosclerosis, were prepared mainly by treatment of I (R1 = OH) with SOCl2 to give I (R1 = Cl) and reaction with alcs. and amines. Thus, I (R = 4-PrCO, R1 = OH, R2 = Cl) and SOCl2 were refluxed in CHCl3 to give the chloride, which reacted with HOCH2CH2NHAc in DMF and Et2O in the presence of pyridine at from 5° to room temperature to give I (R = 4-PrCO, R1 = OCH2CH2NHAc, R2 = Cl).

IT 50819-85-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation and esterification of)

RN 50819-85-7 CAPLUS

CN Benzeneacetic acid, 4-chloro-α-[(4'-chloro[1,1'-biphenyl]-4-yl)oxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1966:93101 CAPLUS
DOCUMENT NUMBER: 64:93101
ORIGINAL REFERENCE NO.: 64:17471e-f
TITLE: Influence of molecular structure on optical properties of systems with carbon asymmetry centers. V. On synthesis of optically active α-(4-biphenylyloxy)phenylacetic acids
AUTHOR(S): Janczewski, Marian; Bilczuk, Luba
CORPORATE SOURCE: Sklodowska Curie Univ., Lublin, Pol.
SOURCE: Roczniki Chemii (1965), 39(12), 1927-9
CODEN: ROCHAC; ISSN: 0035-7677
DOCUMENT TYPE: Journal
LANGUAGE: French

AB cf. CA 60, 14416c. 4-Hydroxybiphenyl heated with the Me ether of α-bromophenylacetic acid (I) and MeONa in anhydrous MeOH medium gave Me α-(4-diphenylyloxy)phenylacetate, m. 119-20° (MeOH). I treated with MeOH + H2O solution of KOH gave racemic α-(4-diphenylyloxy)phenylacetic acid (II), m. 181-2° amide m. 208-9°; p-nitrobenzyl ether m. 145-6°, p-bromo-phenacyl ether m. 121-2°. II was separated by fractional crystallization of neutral salts of cinchonidine into optical antipodes, m. 195-6° with [α]20D -106.06, and m. 194-5° with [α]20D 106.06. Similarly, racemic α-(4-diphenylyloxy)propionic acid was obtained, m. 165-6°. cf. CA 62, 16159g.

IT 106336-82-7P, Acetic acid, (4-biphenylyloxy)phenyl-, compound with cinchonidine (1:1)
RL: PREP (Preparation)

(preparation of)
RN 106336-82-7 CAPLUS
CN Acetic acid, (4-biphenylyloxy)phenyl-, compd. with cinchonidine (7CI) (CA INDEX NAME)

CM 1

CRN 94465-08-4
CMF C20 H16 O3



CM 2

CRN 485-71-2
CMF C19 H22 N2 O

Absolute stereochemistry. Rotation (-).



=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	45.11	217.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.24	-6.24

FILE 'STNGUIDE' ENTERED AT 16:13:55 ON 23 FEB 2007

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 16, 2007 (20070216/UP).

=> d his

(FILE 'HOME' ENTERED AT 16:11:53 ON 23 FEB 2007)

```
     FILE 'REGISTRY' ENTERED AT 16:12:08 ON 23 FEB 2007
L1                STRUCTURE UPLOADED
L2              2 S L1
L3             44 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 16:13:00 ON 23 FEB 2007
L4             17 S L3 FULL
L5              8 S L4 AND PY<2003

     FILE 'STNGUIDE' ENTERED AT 16:13:55 ON 23 FEB 2007

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.66     218.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -6.24

STN INTERNATIONAL LOGOFF AT 16:20:29 ON 23 FEB 2007
```